New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension, Presented at CTAD 2026Benefits of continuous lecanemab treatment in early Alzheimer’s disease accrue over time
Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI
62% of patients with low tau showed improvement in cognitive function and activities of daily living (CDR-SB) at five years

  • R&D
  • Products

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.